Loading…
Aquestive Therapeutics, Inc. is projected to rise to $4.85 by 2027, a +21% move from its current price of $4.00. AQST is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $3.87 | $4.00 | $4.14 | +0.02% |
| May 30 | $3.81 | $4.00 | $4.20 | +0.04% |
| May 31 | $3.77 | $4.00 | $4.24 | +0.05% |
| Jun 1 | $3.74 | $4.00 | $4.28 | +0.07% |
| Jun 2 | $3.71 | $4.00 | $4.32 | +0.09% |
| Jun 3 | $3.69 | $4.00 | $4.35 | +0.11% |
| Jun 4 | $3.66 | $4.01 | $4.38 | +0.13% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $3.66 | $4.01 | $4.38 | +0.13% |
| Week 2 | $3.53 | $4.01 | $4.55 | +0.26% |
| Week 3 | $3.44 | $4.02 | $4.69 | +0.38% |
| Week 4 | $3.36 | $4.02 | $4.81 | +0.51% |
| Week 5 | $3.29 | $4.03 | $4.92 | +0.64% |
| Week 6 | $3.24 | $4.03 | $5.02 | +0.77% |
| Week 7 | $3.18 | $4.04 | $5.12 | +0.90% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. It offers Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; EMYLIF, an oral film formulation of riluzole; ONDIF, an oral soluble film formulation of ondansetron; SYMPAZAN, an oral soluble film formulation of clobazam used for the treatment of seizures associated with a rare, intractable form of epilepsy; KYNMOBI, a sublingual film formulation of apomorphine; and AZSTARYS, an fda-approved, once-daily product for the treatment of ADHD in patients age 6 years or older.
The company's proprietary pipeline products include Anaphylm, an epinephrine sublingual film, which is in phase 3 clinical trial for the emergency treatment of allergic reactions, including anaphylaxis; and AQST-108, a topical gel that is in phase 2 clinical trial for the treatment of alopecia areata. In addition, it develops PharmFilm technology for patients suffering from certain central nervous system disorders; and Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.
AQSTEST is Aquestive Therapeutics, Inc., a healthcare company focused on pharmaceutical products.
A major floor 26.2% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 18.3% above — a clean break opens room to run.
A major ceiling 24.3% above — clearing it would confirm fresh momentum.
Key AQST support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of AQST market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $4.12 | Sell | $4.10 | Sell |
| MA 10 | $4.19 | Sell | $4.14 | Sell |
| MA 20 | $4.19 | Sell | $4.17 | Sell |
| MA 50 | $4.15 | Sell | $4.19 | Sell |
| MA 100 | $4.11 | Sell | $4.33 | Sell |
| MA 200 | $4.88 | Sell | $4.41 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 43.80 | Neutral |
| Stoch RSI (14) | 0.00 | Buy |
| CCI (20) | -136.89 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.03 | Sell |
| ROC (12) | -7.41 | Sell |
| Bollinger %B (20,2) | 0.17 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | 0.04 | Buy |
| Awesome (5,34) | -0.07 | Sell |
| Ultimate (7,14,28) | 36.84 | Neutral |
| Momentum (10) | -0.16 | Sell |
| Aroon Osc (25) | -32.00 | Sell |
| Hull MA (9) | 4.06 | Sell |
| ADX (14) | 8.47 | Neutral |
| ATR (14) | 0.11 | Info |
Current price: $4.12, with a market cap of $516.85M and a rank of 3020. The stock’s current price sits near the $4.12 level as the market position is evaluated.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $2.95 | $4.00 | $5.81 | 0% | Neutral | |
| $3.76 | $4.85 | $6.69 | +21% | Bullish | |
| $3.85 | $5.14 | $7.40 | +29% | Bullish | |
| $3.84 | $5.29 | $7.87 | +32% | Bullish | |
| $4.38 | $6.18 | $9.46 | +55% | Bullish | |
| $5.40 | $7.81 | $12.26 | +95% | Bullish | |
| $5.93 | $8.77 | $14.07 | +119% | Bullish | |
| $6.65 | $10.06 | $16.46 | +151% | Bullish | |
| $6.88 | $10.61 | $17.69 | +165% | Bullish | |
| $6.62 | $10.41 | $17.66 | +160% | Bullish | |
| $10.04 | $17.28 | $31.46 | +332% | Bullish | |
| $15.53 | $31.37 | $63.29 | +684% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $2.95 | $4.00 | $4.73 | +0.00% |
| June 2026 | $3.51 | $4.14 | $5.02 | +3.48% |
| July 2026 | $3.41 | $4.07 | $5.01 | -1.75% |
| August 2026 | $3.34 | $4.02 | $5.02 | -1.08% |
| September 2026 | $3.48 | $4.21 | $5.31 | +4.67% |
| October 2026 | $3.58 | $4.36 | $5.55 | +3.50% |
| November 2026 | $3.55 | $4.35 | $5.58 | -0.19% |
| December 2026 | $3.64 | $4.49 | $5.81 | +3.17% |
Click any year to see its month-by-month AQST forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The AQST price prediction for 2026 points to an average of $4.00 (low $2.95, high $5.81) — a potential gain of 0% on today's $4.00. Price action looks broadly range-bound.
In 2027, AQST is projected to trade between $3.76 and $6.69, averaging $4.85 — a potential gain of +21% from today's $4.00. That is up +21% on the projected 2026 average. Buyers look set to stay in control over this stretch.
Aquestive Therapeutics, Inc.'s 2028 outlook centres on $5.14, within a $3.85 to $7.40 range. That is up +6% on the projected 2027 average. That marks a +29% change versus current levels. Momentum favours further upside here.
By 2029, AQST could reach as high as $7.87, with a base case around $5.29 and support toward $3.84 — roughly +32% from $4.00. Buyers look set to stay in control over this stretch.
Expect AQST to range from $4.38 to $9.46 through 2030. The $6.18 average target implies a +55% move from current prices. That is up +17% on the projected 2029 average. Momentum favours further upside here.
The AQST price prediction for 2031 points to an average of $7.81 (low $5.40, high $12.26) — a potential gain of +95% on today's $4.00. Buyers look set to stay in control over this stretch.
In 2032, AQST is projected to trade between $5.93 and $14.07, averaging $8.77 — a potential gain of +119% from today's $4.00. That is up +12% on the projected 2031 average. Momentum favours further upside here.
Aquestive Therapeutics, Inc.'s 2033 outlook centres on $10.06, within a $6.65 to $16.46 range. That is up +15% on the projected 2032 average. That marks a +151% change versus current levels. Buyers look set to stay in control over this stretch.
By 2034, AQST could reach as high as $17.69, with a base case around $10.61 and support toward $6.88 — roughly +165% from $4.00. Momentum favours further upside here.
Expect AQST to range from $6.62 to $17.66 through 2035. The $10.41 average target implies a +160% move from current prices. That is -2% versus the projected 2034 average. Buyers look set to stay in control over this stretch.
The AQST price prediction for 2040 points to an average of $17.28 (low $10.04, high $31.46) — a potential gain of +332% on today's $4.00. Momentum favours further upside here.
In 2050, AQST is projected to trade between $15.53 and $63.29, averaging $31.37 — a potential gain of +684% from today's $4.00. That is up +82% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in AQST today (≈ 250 AQST) could be worth
$7,843.51
+$6,843.51 (+684%) by 2050 · US Dollar
Based on the average projected AQST price of $31.37 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in AQSTwould be worth at today's price.
$1,000 invested in AQST on May 27, 2025 (≈ 392.15687 AQST) would be worth
$1,568.63
+$568.63 (+56.9%) today · 1.57× · US Dollar
Based on a AQST entry price of $2.55 vs. today's $4.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $4.17 | $959.23 | -4.1% |
| 1 month ago | $4.1 | $975.61 | -2.4% |
| 3 months ago | $4.11 | $973.24 | -2.7% |
| 6 months ago | $6.19 | $646.2 | -35.4% |
| 1 year ago | $2.55 | $1,568.63 | +56.9% |
| All time (5.0y) ago | $3.76 | $1,063.83 | +6.4% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our AQST forecast.
Our base-case forecast reaches $8.00 around 2032.
Implied market cap at $8.00: $1B
The multi-year forecast shows a bullish trajectory after 2026, with average target prices rising over time. In 2030, the average forecast price is $6.37 with a 54.7% ROI, and in 2050 the average forecast price is $32.96 with a 700% ROI. The early years (2026–2029) are neutral to bullish, with the 2026 average price at $4.12 and a 0% ROI, then progressively stronger upside through 2030 and beyond as depicted by the rising averages and high-positive ROIs in subsequent years.
The forecast entries for 2040 and 2050 show substantial upside, with averages of $17.92 and $32.96 and ROIs of 335% and 700%, respectively. These projections carry inherent uncertainty and are not guaranteed, reflecting a wide range of potential outcomes. The 2026–2050 period is marked as bullish, with volatility noted at an annualized rate of 70% in the technical picture.
Tap a question to reveal the answer.
Avg price $6.37; min $4.45; max $9.89; ROI 54.7%; sentiment BULLISH.
Forecasts show a bullish sentiment from 2027 onward with rising average targets, culminating in a 2030 average of $6.37 and a 54.7% ROI. These are estimates and carry uncertainty.
Yes. The 2050 forecast shows a max of $68.02, with an average of $32.96 and a 700% ROI, though this remains an estimate.
$3.26 to $5.21.
Current price is $4.12 and market cap is $516.85M.
Aquestive Therapeutics, Inc. Community Discussion
0Share your Aquestive Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.